18.10.2014 Views

Annual Report 2002 - Agfa

Annual Report 2002 - Agfa

Annual Report 2002 - Agfa

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS<br />

The reconciliation of Cash and cash equivalents with its corresponding balance<br />

sheet items can be presented as follows:<br />

16. Cash and cash equivalents<br />

MILLION EUROS <strong>2002</strong> 2001<br />

Marketable securities and other instruments 12 2<br />

Cash on hand, demand deposits and checks 133 222 *<br />

Total Cash and cash equivalents as reported<br />

in the Balance Sheet 145 224<br />

Accounts receivable under cash management agreements<br />

(reported in the balance sheet as Other receivables) - 3<br />

Liabilities under cash management agreements<br />

(reported in the balance sheet as Miscellaneous liabilities) (4) (7)<br />

Revaluation financial assets available-for-sale - 3<br />

Total Cash and cash equivalents as reported<br />

in the Cash Flow Statement 141 223<br />

* Included is an amount of 97 million Euros that has been deposited into an escrow<br />

account in relation to the acquisition of Mitra Inc. This amount represented<br />

a portion of the purchase price of Mitra Inc. (note 4).<br />

The various components of Shareholders’ Equity and the changes therein from<br />

December 31, 2001 to December 31, <strong>2002</strong> are presented in the Consolidated<br />

Statements of Shareholders’ Equity.<br />

17. Shareholders’ equity<br />

Capital stock<br />

The issued capital of the Company as of December 31, <strong>2002</strong> amounts to 140 million<br />

Euros, represented by 140,000,000 fully paid ordinary shares without par value.<br />

Reserve for own shares<br />

The reserve for the Company’s own shares comprises the cost of the Company’s<br />

shares held by the Group. At December 31, <strong>2002</strong> the Group held 768,400<br />

(2001: 150,000) of the Company’s shares (note 18 B).<br />

Revaluation reserve<br />

In order to manage the price risk on its Long Term Incentive Plan (tranche n° 2)<br />

the Company deposited 10.2 million Euros, pledged in favour of an investment<br />

banker. This available-for-sale financial asset was revalued to fair value with<br />

cumulative changes taken into the revaluation reserve (note 18 B).<br />

The revaluation reserve moreover comprises the revaluation of our investment in<br />

Medivision Medical Imaging Ltd. (December 31, <strong>2002</strong>: -2 million Euros).<br />

<strong>Agfa</strong> annual report <strong>2002</strong><br />

70

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!